{"groups":[{"id":"FG000","title":"Anakinra With/Without Dexamethasone"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"8"}],"type":"Alternative Treatment"},{"reasons":[{"groupId":"FG000","numSubjects":"4"}],"type":"Other"},{"reasons":[{"groupId":"FG000","numSubjects":"21"}],"type":"Still on treatment"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"54"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"21"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"33"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Patients received induction therapy of Anakinra alone for 6 months. Based on response, dexamethasone could be added or increased in subsequent cycles. See the Outline section for more detail. Unless otherwise stated, results are reported for all patients (regardless of dexamethasone administration).","recruitmentDetails":"55 patients were recruited from November 2002 through December 2007 at Mayo Clinic.\n\nOne patient had progressive disease prior to starting treatment. This patient was excluded from all analysis."}